Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.83 +0.06 (+0.23%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 
Via InvestorPlace
Will Alphabet 'Storm Back?' Plus: Progressive, D.R. Horton And Pfizer On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Pfizer Inc. 
Via Benzinga
7 Elite Blue-Chip Stocks Predicted to Double Your Fortune by 2028
Explore three elite blue-chip stocks in interactive media, transaction processing, semiconductors, pharmaceuticals, and telecommunication. 
Via InvestorPlace
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
From Pfizer Inc.
Via Business Wire
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 12, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma
Pfizer's Phase 3 study reveals Adcetris combo significantly improves overall survival in relapsed/refractory DLBCL. Positive outcomes in progression-free survival and overall response rate. 
Via Benzinga
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
From Pfizer Inc.
Via Business Wire
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 11, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pfizer Shifts Strategic Focus, Pivoting From COVID To Cancer Drugs To Recover Market Value
Pfizer navigates a strategic shift from Covid to cancer drugs, targeting a 65% biologics share in the oncology pipeline by 2030. With a $43 billion Seagen acquisition doubling experimental programs. 
Via Benzinga
Exposures COVID-19
Apple And 4 More Stocks On The Rise: Prime Reddit Picks
Investors seek undervalued stocks in current market. Redditors share value picks, including Apple, Alphabet, Crocs, Starbucks, and Pfizer. 
Via Benzinga
2 Dirt Cheap Dividend Stocks to Buy and Hold
These companies aren't popular on the market right now, but income investors will like them. 
Via The Motley Fool
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
There are some great companies at attractive prices in the lucrative pharmaceutical space. 
Via The Motley Fool
1 Bruised Dividend Stock to Buy While It's Cheap, and 1 to Avoid
Having a viable recovery plan is key. 
Via The Motley Fool
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 10, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks
With therapeutics focused on slimming down skyrocketing, it’s time to consider these top weight-loss stocks. 
Via InvestorPlace
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run
These stocks are trading down, but investors may be overlooking some important points. 
Via The Motley Fool
3 Dividend Stocks to Buy Hand Over Fist in March
Income investors might want to load up on these great dividend stocks. 
Via The Motley Fool
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 09, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
Exposures Product Safety
BNTX DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
BNTX DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - March 08, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.